Chance to Change Pricing Generally Required After Corrective Action
Client Alert | 1 min read | 10.27.11
The GAO in Power Connector, Inc. (Aug. 15, 2011), reiterated that, when an agency changes a solicitation evaluation criteria in a material way as part of corrective action, it must allow offerors in the next round of proposals to alter their price – even when the change has no obvious relationship to pricing – because the offeror may have submitted a more competitive price had it known that its proposal would be less competitive in another evaluation area. In response to agency concerns about the protestor having an unfair advantage in the recompetition as a result of learning of other offerors’ pricing during its debriefing, GAO instructed that the proper remedy was to level the playing field by disclosing all prices to all offerors, rather than to forbid price changes.
For further analysis, click here for related blog post by James Peyster.
Contacts
Insights
Client Alert | 4 min read | 01.07.26
On December 17, 2025, the U.S. Food and Drug Administration (FDA) issued a request for information (RFI) on a proposal designed to help the FDA engage more directly with innovative, venture-backed companies focused on biotechnology, medical devices, AI, and regulatory technology.[i]The RFI includes 19 questions, with responses due by 2:00 p.m. ET on January 18, 2026.
Client Alert | 3 min read | 01.07.26
CMMC for AI? Defense Policy Law Imposes AI Security Framework and Requirements on Contractors
Client Alert | 3 min read | 01.07.26
New Year, Same CIPA Uncertainty – When Will the Appellate Courts Enter the Chat?
Client Alert | 11 min read | 01.07.26
